1. Homepage
  2. Equities
  3. India
  4. Bombay Stock Exchange
  5. Pfizer Limited
  6. News
  7. Summary
    500680   INE182A01018

PFIZER LIMITED

(500680)
  Report
End-of-day quote Bombay Stock Exchange  -  05-22
4407.35 INR   +1.27%
05/20Pfizer Limited Recommends Dividend for the Financial Year Ended March 31, 2022, Payable on or before September 23, 2022
CI
05/20Pfizer Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022
CI
05/20Pfizer Limited Reports Earnings Results for the Full Year Ended March 31, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Israeli study shows 4th shot of COVID-19 vaccine less effective on Omicron

01/17/2022 | 11:38am EDT
Senior citizens receive a fourth dose of the COVID-19 vaccine at a vaccination party in Israel

JERUSALEM, Jan 17 (Reuters) - A fourth shot of COVID-19 vaccine boosts antibodies to even higher levels than the third jab but it is not enough to prevent Omicron infections, according to a preliminary study in Israel.

Israel's Sheba Medical Center has given second booster shots in a trial among its staff and is studying the effect of the Pfizer booster in 154 people after two weeks and the Moderna booster in 120 people after one week, said Gili Regev-Yochay, director of the Infectious Diseases Unit.

These were compared to a control group that did not receive the fourth shot. Those in the Moderna group had previously received three shots of Pfizer's vaccine, the hospital said.

The vaccines led to a increase in the number of antibodies "even a little bit higher than what we had after the third dose," said Regev-Yochay.

"Yet, this is probably not enough for the Omicron," she told reporters. "We know by now that the level of antibodies needed to protect and not to got infected from Omicron is probably too high for the vaccine, even if it's a good vaccine."

The findings, which the hospital said were the first of its kind in the world, were preliminary and not yet published.

Israel was the fastest country to roll out initial vaccinations against COVID-19 a year ago and last month started offering a fourth shot, or a second booster, to the most vulnerable and high-risk groups. (Reporting by Ari Rabinovitch Editing by Mark Heinrich)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. 1.24% 137.945 Delayed Quote.-46.35%
ON SEMICONDUCTOR CORPORATION -1.31% 55.69 Delayed Quote.-16.87%
PFIZER LIMITED 1.27% 4407.35 End-of-day quote.-12.72%
All news about PFIZER LIMITED
05/20Pfizer Limited Recommends Dividend for the Financial Year Ended March 31, 2022, Payable..
CI
05/20Pfizer Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022
CI
05/20Pfizer Limited Reports Earnings Results for the Full Year Ended March 31, 2022
CI
04/10ResApp Has Entered into A Research & Development Licence Agreement with Pfizer
CI
03/03Pfizer and FDA Dropped Data Bombshell on Covid Vaccine Consumers
CI
02/07Pfizer India Appoints New Chairman
MT
02/04Pfizer Posts Rise in Fiscal Q3 Net Profit
MT
02/03Pfizer Limited Announces Board Changes
CI
02/02Pfizer Limited Announces Resignation of R. A. Shah as an Independent Director
CI
01/28Eli Lilly says FDA could deny expanded use of arthritis drug for eczema
RE
More news
Analyst Recommendations on PFIZER LIMITED
More recommendations
Financials
Sales 2022 26 579 M 343 M 343 M
Net income 2022 6 555 M 84,6 M 84,6 M
Net Debt 2022 - - -
P/E ratio 2022 32,8x
Yield 2022 0,86%
Capitalization 202 B 2 602 M 2 602 M
Capi. / Sales 2022 7,59x
Capi. / Sales 2023 7,30x
Nbr of Employees 2 358
Free-Float 33,2%
Chart PFIZER LIMITED
Duration : Period :
Pfizer Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 4 407,35
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Sridhar Subramaniam Managing Director & Executive Director
Milind Patil Chief Financial Officer & Executive Director
Navin Singhania Director-Business Technology
Sonali Dighe Senior Director-Medical Affairs
Prajeet Nair Secretary & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER LIMITED-12.72%2 559
JOHNSON & JOHNSON3.45%465 705
PFIZER, INC.-11.14%294 404
ELI LILLY AND COMPANY8.19%269 013
ABBVIE INC.11.53%266 851
ROCHE HOLDING AG-15.67%266 707